RECOURSE Study Finds TAS-102 Effective in Colorectal Cancer

June 7, 2015
Atsushi Ohtsu, MD, PhD

In this video, Dr. Atsushi Ohtsu discusses the use of TAS-102, an oral combination of trifluridine and tipiracil hydrochloride, in refractory colorectal cancer.

In this video, Dr. Atsushi Ohtsu discusses the use of TAS-102, an oral combination of trifluridine and tipiracil hydrochloride, in refractory colorectal cancer.

Related Content:

ASCO | Gastrointestinal Cancer